Massive 99,000-Person study checks if paxlovid prevents severe COVID
NCT ID NCT07261085
Summary
This study uses real-world health records from Ontario to see if the COVID-19 treatment Paxlovid helps prevent severe outcomes like hospitalization or death. It compares the experiences of adults who received the drug at a pharmacy to those who did not, tracking their health for up to 60 days. The goal is to understand the medicine's effectiveness in everyday use outside of controlled clinical trials.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COVID-19 are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Pfizer New York
New York, New York, 10001, United States
Conditions
Explore the condition pages connected to this study.